These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18265796)

  • 21. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status of anti-vascular endothelial growth factor therapy in Europe.
    Wolf S
    Jpn J Ophthalmol; 2008; 52(6):433-439. PubMed ID: 19089562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration.
    Dadgostar H; Waheed N
    Eye (Lond); 2008 Jun; 22(6):761-7. PubMed ID: 18388961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegaptanib for the treatment of age-related macular degeneration.
    Zhou B; Wang B
    Exp Eye Res; 2006 Sep; 83(3):615-9. PubMed ID: 16678158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiangiogenic therapy in neovascular age-related macular degeneration.
    Lin RC; Rosenfeld PJ
    Int Ophthalmol Clin; 2007; 47(1):117-37. PubMed ID: 17237677
    [No Abstract]   [Full Text] [Related]  

  • 27. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
    Nagpal M; Nagpal K; Nagpal PN
    Indian J Ophthalmol; 2007; 55(6):437-9. PubMed ID: 17951900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment].
    Wylegała E; Teper SJ
    Klin Oczna; 2007; 109(1-3):97-100. PubMed ID: 17687925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical update: new treatments for age-related macular degeneration.
    Wong TY; Liew G; Mitchell P
    Lancet; 2007 Jul; 370(9583):204-206. PubMed ID: 17658379
    [No Abstract]   [Full Text] [Related]  

  • 30. Debate on the various anti-vascular endothelial growth factor drugs.
    Khalili MR; Hosseini H
    Indian J Ophthalmol; 2008; 56(3):255-6; author reply 256. PubMed ID: 18417837
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
    Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
    Maier M; Feucht N; Huebner M; Lohmann C
    Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    ; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
    Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
    Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR; Moride Y; Rochon S
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ranibizumab in neovascular age-related macular degeneration.
    Kenneth TE; Kertes PJ
    Clin Interv Aging; 2006; 1(4):451-66. PubMed ID: 18046922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effect comparison of ranibizumab and sodium pegaptanib on the retinal pigment epithelium ablation size in the treatment of age-related macular degeneration].
    Sin M; Jakubcová M; Chrapek O; Pracharová Z; Simicák J; Rehák J
    Cesk Slov Oftalmol; 2012 May; 68(2):57-60. PubMed ID: 22913867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.
    Kaiser PK
    Am J Ophthalmol; 2006 Oct; 142(4):660-8. PubMed ID: 17011860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
    Athanasakis K; Fragoulakis V; Tsiantou V; Masaoutis P; Maniadakis N; Kyriopoulos J
    Clin Ther; 2012 Feb; 34(2):446-56. PubMed ID: 22289279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.